-
Sector Analysis
NewAmyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029
Amyotrophic Lateral Sclerosis Market Report Overview Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a severely debilitating, rare, and ultimately fatal neurodegenerative condition caused by a combination of genetic and environmental factors. However, the causative pathogenic mechanisms in ALS remain unclear. The condition is characterized by progressive degeneration of both upper (UMNs) and lower motor (LMNs) neurons that leads to death, frequently from respiratory failure, within a few years. The 8MM includes the US, France, Germany,...
-
Product Insights
NewNet Present Value Model: BrainStorm Cell Therapeutics Inc’s NurOwn
Empower your strategies with our Net Present Value Model: BrainStorm Cell Therapeutics Inc's NurOwn report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – BrainStorm Cell Therapeutics Inc
BrainStorm Cell Therapeutics Inc (BrainStorm Cell Therapeutics), formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote...
-
Sector Analysis
Cell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Product Insights
NewPrimary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024
Empower your strategies with our Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and...
-
Product Insights
NewSecondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewPeripheral Nerve Injury – Drugs In Development, 2024
Empower your strategies with our Peripheral Nerve Injury – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral nerve injuries pose various challenges to patients, ranging from mild discomfort to life-long impairment. Peripheral nerve injuries include brachial plexus injury, peroneal nerve injury (foot drop), and spinal accessory nerve injury. The Peripheral Nerve Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Peripheral Nerve Injury, complete with analysis by stage of development,...
-
Product Insights
NewHuntington Disease – Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...